GENB Short Volume
Generate Biomedicines, Inc. (GENB) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $1.68B, listed on NASDAQ, employing roughly 312 people, carrying a beta of 0.00 to the broader market. Generate Biomedicines, Inc. Led by Michael T. Nally, public since 2026-02-27.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-06-01
- Short Volume
- 168.2K
- Total Volume
- 265.3K
- Short %
- 63.41%
- 30-Day Avg Short %
- 60.81%
Showing 30 days of FINRA short volume data for Generate Biomedicines, Inc..
Learn how short volume is reported and how to read the data →
Frequently asked GENB short volume questions
- What is the daily GENB short volume?
- As of Jun 1, 2026, Generate Biomedicines, Inc. (GENB) short volume is 168.2K shares against 265.3K total reported volume, or 63.41% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is GENB short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does GENB short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.